Edition:
United Kingdom

Sonoma Pharmaceuticals Inc (SNOA.OQ)

SNOA.OQ on NASDAQ Stock Exchange Capital Market

3.82USD
18 May 2018
Change (% chg)

$0.02 (+0.53%)
Prev Close
$3.80
Open
$3.79
Day's High
$3.82
Day's Low
$3.79
Volume
4,637
Avg. Vol
19,701
52-wk High
$7.75
52-wk Low
$3.50

Chart for

About

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets solutions for management of dermatological conditions and advanced tissue care. The Company's product portfolio consists of dermatology, animal health, and advanced tissue care products based upon its Microcyn technology. Its Microcyn... (more)

Overall

Beta: 1.23
Market Cap(Mil.): $22.06
Shares Outstanding(Mil.): 4.31
Dividend: --
Yield (%): --

Financials

  SNOA.OQ Industry Sector
P/E (TTM): -- 30.95 32.75
EPS (TTM): -2.11 -- --
ROI: -66.04 14.84 14.38
ROE: -68.22 16.34 16.07

BRIEF-Sonoma Pharma Receives Four New Uae Regulatory Approvals That Include Acne And Anti-Fungal Products

* SONOMA PHARMACEUTICALS RECEIVES FOUR NEW UAE REGULATORY APPROVALS THAT INCLUDE ACNE AND ANTI-FUNGAL PRODUCTS

17 Apr 2018

BRIEF-Sonoma Pharmaceuticals Announces FDA Approval For Antimicrobial Post Therapy Gel

* ANNOUNCES FDA APPROVAL FOR ANTIMICROBIAL POST THERAPY GEL Source text for Eikon: Further company coverage:

05 Apr 2018

BRIEF-Montreux Equity Partners Reports 9.26 Pct Passive Stake In Sonoma Pharmaceuticals

* MONTREUX EQUITY PARTNERS REPORTS 9.26 PERCENT PASSIVE STAKE IN SONOMA PHARMACEUTICALS AS OF MARCH 2 - SEC FILING Source text: (http://bit.ly/2FvWSFR) Further company coverage:

09 Mar 2018

BRIEF-Sonoma Pharmaceuticals Closes $5 Million Public Offering

* SONOMA PHARMACEUTICALS ANNOUNCES CLOSING OF $5 MILLION PUBLIC OFFERING OF COMMON STOCK

07 Mar 2018

BRIEF-Sonoma Pharmaceuticals Announces Pricing Of $5 Mln Public Offering Of Common Stock

* SONOMA PHARMACEUTICALS ANNOUNCES PRICING OF $5 MILLION PUBLIC OFFERING OF COMMON STOCK

02 Mar 2018

BRIEF-Sonoma Pharma Revenue $4.8 Million For Third Quarter

* SONOMA PHARMACEUTICALS REPORTS RECORD TOTAL REVENUE OF $4.8 MILLION FOR THIRD QUARTER FY 2018 WITH YEAR OVER YEAR PRODUCT REVENUE GROWTH OF 46%

07 Feb 2018

BRIEF-Sonoma Pharma Gets Three New UAE Regulatory Approvals

* SONOMA PHARMACEUTICALS RECEIVES THREE NEW UNITED ARAB EMIRATES REGULATORY APPROVALS: ACUICYN® FOR MANAGEMENT OF BLEPHARITIS, MICROSAFE® ORAL CARE FOR MUCOSITIS AND SINUDOX® FOR CHRONIC SINUSITIS

09 Jan 2018

BRIEF-Sonoma Pharmaceuticals announces second FDA approval to add antimicrobial language to alevicyn gel products

* SONOMA PHARMACEUTICALS ANNOUNCES SECOND FDA APPROVAL TO ADD ANTIMICROBIAL LANGUAGE TO ALEVICYN™ GEL PRODUCTS FOR MANAGEMENT OF ATOPIC DERMATITIS Source text for Eikon: Further company coverage:

05 Dec 2017

Earnings vs. Estimates